[{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Florbetaben","moa":"Amyloid","graph1":"Neurology","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Life Molecular Imaging \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ Undisclosed"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"pharmtrace","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Florbetaben","moa":"Amyloid","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Life Molecular Imaging \/ pharmtrace","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ pharmtrace"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"pharmtrace klinische Entwicklung","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F Florbetaben","moa":"Amyloid-beta-plaque","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Life Molecular Imaging \/ pharmtrace klinische Entwicklung","highestDevelopmentStatusID":"10","companyTruncated":"Life Molecular Imaging \/ pharmtrace klinische Entwicklung"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Life Molecular Imaging","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"18-F GP1","moa":"GPIIb\/IIIa","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Life Molecular Imaging \/ Life Molecular Imaging","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ Life Molecular Imaging"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"68-Ga RM2","moa":"GRPr","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Life Molecular Imaging \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Life Molecular Imaging \/ Undisclosed"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"18-F FSPG","moa":"System xC- transporter","graph1":"Oncology","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Life Molecular Imaging \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ Undisclosed"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Life Molecular Imaging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"18-F MNI-815","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Life Molecular Imaging \/ Life Molecular Imaging","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ Life Molecular Imaging"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Life Molecular Imaging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"18-F PI2620","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Life Molecular Imaging \/ Life Molecular Imaging","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ Life Molecular Imaging"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F PI2620","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Life Molecular Imaging \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ Undisclosed"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Walter Reed National Military Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F PI-2620","moa":"Tau aggregation","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Life Molecular Imaging \/ Walter Reed National Military Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ Walter Reed National Military Medical Center"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F PI-2620","moa":"Tau aggregation","graph1":"Neurology","graph2":"Phase III","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Life Molecular Imaging \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Life Molecular Imaging \/ Undisclosed"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2010","type":"Inapplicable","leadProduct":"68-Ga Bombesin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Life Molecular Imaging \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ Undisclosed"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"BAY1006578","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Life Molecular Imaging \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ Undisclosed"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"BAY1075553","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Life Molecular Imaging \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ Undisclosed"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"BAY86-9596","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Life Molecular Imaging \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ Undisclosed"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"BAY86-9596","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Life Molecular Imaging \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ Undisclosed"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"BAY94-9392","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Life Molecular Imaging \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ Undisclosed"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"BAY94-9392","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Life Molecular Imaging \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Life Molecular Imaging

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Florbetaben is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Amyloidosis, Hereditary, Transthyretin-Related.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 24, 2025

                          Lead Product(s) : Florbetaben

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : pharmtrace

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : 18-F PI-2620 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Alzheimer Disease.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          December 08, 2022

                          Lead Product(s) : 18-F PI-2620

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : 18-F PI-2620 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Brain Concussion.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          April 20, 2022

                          Lead Product(s) : 18-F PI-2620

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase I

                          Sponsor : Walter Reed National Military Medical Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : 18-F PI2620 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Supranuclear Palsy, Progressive.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          January 12, 2022

                          Lead Product(s) : 18-F PI2620

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : 18-F Florbetaben is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Amyloidosis, Hereditary, Transthyretin-Related.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          January 11, 2022

                          Lead Product(s) : 18-F Florbetaben

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : pharmtrace klinische Entwicklung

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : 18-F PI2620 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          January 20, 2021

                          Lead Product(s) : 18-F PI2620

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Life Molecular Imaging

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : 18-F MNI-815 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          August 24, 2015

                          Lead Product(s) : 18-F MNI-815

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Recipient : Molecular NeuroImaging

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : 68-Ga RM2 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          June 29, 2015

                          Lead Product(s) : 68-Ga RM2

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : 18-F GP1 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Aortic Aneurysm, Abdominal.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          June 11, 2015

                          Lead Product(s) : 18-F GP1

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Recipient : University of Zurich

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : 18-F FSPG is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Brain Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          February 25, 2015

                          Lead Product(s) : 18-F FSPG

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank